Abstract Human estrogen receptors alpha and beta are crucially involved in the regulation of mammary growth and development. Normal breast tissues display a relative higher expression of ER beta than ER alpha, which drastically changes during breast tumorogenesis. Thus, it is reasonable to suggest that a dysregulation of the two estrogen receptor subtypes may induce breast cancer development. However, the molecular mechanisms underlying the potential opposing roles played by the two estrogen receptors on tumor cell growth remain to be elucidated. In the present study, we have demonstrated that ER beta overexpression in breast cancer cells decreases cell proliferation and down-regulates ER alpha mRNA and protein content, along with a concomitant repression of estrogen-regulated genes. Transient transfection experiments, using a vector containing the human ER alpha promoter region, showed that elevated levels of ER beta down-regulated basal ER alpha promoter activity. Furthermore, site-directed mutagenesis and deletion analysis revealed that the proximal GC-rich motifs at -223 and -214 are critical for the ER beta-induced ER alpha down-regulation in breast cancer cells. This occurred through ER beta-Sp1 protein-protein interactions within the ER alpha promoter region and the recruitment of a corepressor complex containing the nuclear receptor corepressor NCoR, accompanied by hypoacetylation of histone H4 and displacement of RNA-polymerase II. Silencing of NCoR gene expression by RNA interference reversed the down-regulatory effects of ER beta on ER alpha gene expression and cell proliferation. Our results provide evidence for a novel mechanism by which overexpression of ER beta through NCoR is able to down regulate ER alpha gene expression, thus blocking ER alpha's driving role on breast cancer cell growth.
Introduction
Estrogens play an important role in mammary gland development, but they are also involved in mammary carcinogenesis [1, 2] . These steroid hormones exert their biological effects via interaction with the two different isoforms of estrogen receptors, ER alpha, and ER beta, each encoded by unique genes, but with a common structural and functional organization. Binding of estrogen ligands to ERs in the nucleus results in receptor phosphorylation, dimerization, and recruitment of specific coregulator proteins, termed coactivators, which enhance binding of the receptor complex to promoter regions of target genes known as estrogen response elements (EREs) and augment receptor's transcriptional activity [3, 4] . In addition to these genomic actions, ERs, located in the cell membrane or cytoplasm, may initiate rapid cellular signaling, and are involved in intricate networks of crosstalk with growth factor pathways [5] [6] [7] . In addition, ERs may bind to DNA in a non classical way through its interaction with other transcription factors. For instance, ER alpha/Sp1, ER alpha/AP-1, and ER beta/ Sp-1, ER beta/AP-1-mediated gene regulation through binding GC-rich and AP-1 motifs have been extensively investigated [8] [9] [10] [11] [12] . Indeed, the latter indirect mechanisms may occur in the absence of natural ligand, in a cell type and gene dependent context [12] [13] [14] [15] , and may also involve recruitment of corepressors such as NCoR and SMRT to inhibit basal cell transcription machinery [16, 17] .
Both ERs subtypes are expressed in human mammary tissue with only 7-10 % of the epithelial cells expressing ER alpha but 80-85 % expressing ER beta [18] [19] [20] . In contrast, expression of ER alpha is increased in breast cancer cells, where it acts as a mediator of cell proliferation and has been shown to be an effective therapeutic target for decades [21] . The role of ER beta in breast cancer is less clear and its prognostic value is still under debate. It is estimated that ER beta is expressed in approximately onehalf of human primary breast cancers, but its expression is lost during breast cancer progression, most likely due to promoter hypermethylation [22] . Moreover, ER beta protein levels have been linked to good prognosis, prolonged disease-free survival and response to anti-estrogen treatment [23, 24] . Many cell-based studies suggest that ER beta acts as a negative modulator of ER alpha action and can negatively regulate breast cancer proliferation [25] [26] [27] . Indeed, inducible expression of ER beta in ER alphapositive breast cancer cells inhibited estrogen-stimulated proliferation, tumor angiogenesis, and growth in xenograft experiments [28, 29] . Overexpression of ER beta or ER beta cx isoforms also decreased ER alpha transcriptional activity concomitantly with a reduced expression of estrogen-regulated genes, such as vascular endothelial growth factor (VEGF) or progesterone receptor (PR) [30] [31] [32] . In ER-negative cells ectopically expressing the two ERs, ER beta reduced the sensitivity of the cells to estrogen treatment on growth and inhibited cyclin D1 gene activation [33] [34] [35] [36] .
Given the markedly enhanced ratio of ER alpha/ER beta in early breast cancers and the opposite roles of the two ERs in regulating cell proliferation and differentiation, it is imperative to dissect the molecular mechanisms underlying the dysregulation of these processes in cancer cells. Therefore, the aim of this study was to investigate if ER beta may play a direct inhibitory role on ER alpha expression and gene promoter activity. Here, we demonstrate that ER beta through its interaction with Sp1 protein recruits NCoR corepressor in the promoter region upstream the transcription start site of ER alpha gene, thus down-regulating its expression.
Materials and methods
Reagents and antibodies DEMF-12 Ham and DMEM were purchased from Invitrogen (Carlsbad, CA, USA), FuGENE 6, Sp-1 human recombinant protein from Promega (Madison, WI, USA). The RETROscript kit from Ambion (Austin, TX, USA). MTT, IGF-1 by Sigma (Milan, Italy). Antibodies against ER alpha/ER beta/IRS-1/cyclinD1/pS2/GAPDH/NCoR/Sp-1/SMRT/AcH4/PolymeraseII were provided by Santa Cruz Biotechnology (Santa Cruz, CA, USA). SYBR Green by Biosystems (Forster City, CA, USA).
Cell cultures
MCF-7 and ZR75 breast cancer cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA), and maintained as recommended.
Plasmids
The plasmids containing the human ER alpha promoter region or its deletions (E:p -4100/? 212; D:p -2769/ ? 212; C:p -1000/? 212, A:p -245/? 212) were provided by Prof Fuqua [37] . Deletion of Sp-1 site in C plasmid was generated by PCR using following primers: forward 5
0 -GCGGTACCCGAAAGATCGAGTTGTAGGA C-3 0 and reverse 5 0 -CGCTCGAGTTATATAGGGAAGA CTGGGCTTAAAATA-3 0 . The amplified DNA fragment was digested with Kpn I and Xho I and ligated into pGL3-basic vector. The sequence was confirmed by nucleotide sequence analysis. The plasmid encoding the human ER beta was a gift from JA Gustafsson (Karolinska Institute, Sweden).
Site-directed mutagenesis
The mutation of the two half-ERE sites in C plasmid was created by site-directed mutagenesis using QuickChange kit (Stratagene, La Jolla, CA). The mutagenic primers were: forward 5 0 -CATAATTGCCTTTGCTTTGGTTCGT GGTTTGAGGTTATGTTTGGTATGAAAAG-3 0 , 5 0 -CGT GACCTGAGGTTATGTTTGGTATGAAAAGACTACAT TTTATATTCAGTTTTCTGAAG-3 0 , and reverse 5 0 -CTTT TCATACCAAACATAACCTCAAACCACGAACCAAAG CTTTGGCAATTATG-3 0 , 5 0 -CTTCAGAAAACTGAATA TAAAATGTAGTCTTTTCATACCAAACATAACCTCAG GTCACG-3 0 . Mutation was confirmed by DNA sequencing.
Western blot analysis
Equal amounts of cell extracts were subjected to SDS-PAGE, as described [38] . Blots are representative of at least three independent experiments. 0 (GAPDH). The relative gene expression levels were calculated as described [14] .
RT
Transient transfection assays MCF-7 cells were transfected using FuGENE6 reagent with the indicated constructs for 16 h. Luciferase activities were assayed as described [38] .
Electrophoretic mobility shift assay Nuclear extracts were prepared as previously described [39] . The DNA sequences used as probe or as cold competitor are the following:
0 , 5 0 -CACGGCCAGGGGTATGGGGCGCA CGA-3 mutated Sp-1. Probe generation and the proteinbinding reactions were carried out as described [38] . The reaction mixture was incubated with specific antibodies at 4°C for 12 h before addition of labeled probe.
RNA interference MCF-7 cells were co-transfected with an empty vector or an ER beta expression vector and RNA duplex of stealth RNAi-targeted human NCoR mRNA sequence 5 0 -UUG UUUGGCUCUGGAGACCUCUUGC-3 0 or with a stealth RNAi-negative control using Lipofectamine2000 as recommended.
ChIP and Re-ChIP assays
The DNA/protein complexes were extracted as previously described [38] . The precleared chromatin was immunoprecipitated with anti-Sp-1/NCoR/SMRT/AcH4/PoymeraseII antibodies. The anti-Sp-1 immunoprecipitated samples were re-immunoprecipitated with an anti-NCoR or anti-ER beta antibodies. Sample and input DNA (5 ll) were used for PCR amplification with the following primers flanking Sp-1 sequence present in the ER alpha promoter region: 5 0 -G CACATAAGGCAGCACATTA-3 0 (forward), and 5 0 -TG GCTTAAACATCACTCCAG-3 0 (reverse). In another set of experiments, each sample and input DNA (5 ll) were used for real-time PCR using the following primers:
0 . Real-time PCR was performed as described above. Final results were calculated using DDCt method, using input Ct values instead of the GAPDH mRNA. The basal sample was used as calibrator.
Cell proliferation assay
Cell proliferation was determined by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan (MTT) assay as described [40] . Data are representative of three independent experiments, performed in triplicate.
Three-dimensional spheroid culture assays MCF-7 cells plated in 2 % agar-coated plates were transfected as indicated and treated or not with IGF-1. After 48 h, cultures were photographed using a phase-contrast microscope (Olympus, Milan, Italy). Aggregation extent and cell numbers were evaluated as reported [15] . Data represent three independent experiments, performed in triplicate.
Statistical analysis
Data were analyzed for statistical significance using a twotailed student's Test, performed by Graph Pad Prism 4.
Results

ER beta overexpression down-regulates ER alpha expression in breast cancer cells
Although data demonstrate that ER beta negatively interferes with ER alpha signaling in breast cancer cells, it still remains unexplored if ER beta actually affects ER alpha gene expression. To this aim, ER alpha-positive MCF-7 and ZR75 breast cancer cells were transiently transfected with an ER beta expression vector and ER alpha expression was evaluated by RT-PCR and western blotting analysis. As shown in Fig. 1a , b, ectopically expressed ER beta reduced ER alpha levels in terms of mRNA and protein content in both MCF-7 and ZR75 cells. Concomitantly, ER beta overexpression markedly decreased mRNA levels ( Fig. 1c) and protein ( Fig. 1d ) expression of classical estrogen-regulated genes, such as insulin receptor substrate 1 (IRS-1), pS2 and cyclin D1 in both cell lines. These findings correlated well with a dose-dependent inhibition induced by ER beta overexpression on cell proliferation, as revealed by MTT assays (Fig. 1e ).
Overexpressed ER beta mediates down-regulation of ER alpha via a GC proximal region of its promoter
To analyze how ER beta interferes with ER alpha gene transcription, we transiently transfected breast cancer cell lines with a luciferase reporter plasmid containing the human ER alpha promoter region spanning from -4,100 bp to ?212 bp. As shown in Fig. 2a , a significant decrease in ER alpha promoter activity was observed in MCF-7 cells when ER beta was overexpressed. The human ER alpha promoter contains multiple consensus sites for several transcription factors, including a CAT box, TFIID, AP2c, and Sp-1 motifs [37] . To identify the regions within the ER alpha promoter responsible for ER beta-mediated inhibitory effects, we transiently transfected MCF-7 cell lines with plasmids containing a series of 5 0 deleted segments of this human ER alpha promoter. Schematic representation of these constructs is shown in Fig. 2 . In transfection experiments performed using p-4100/? 212 (E), p-2769/? 212 (D), and p-1000/? 212 (C) plasmids, the responsiveness to ER beta was still maintained (Fig. 2a) , suggesting that the region between -1000 and ?212 might be involved in the transrepression mechanisms exerted by ER beta overexpression. Thus, we focused our attention on the latter construct p-1000/? 212 (C), and we identified, upstream to the initiation transcription site, two half ERE (-867/-861 and -894/-888) and one Sp-1 (-223-214) sites, which are putative effectors of ER signaling. We observed that in MCF-7 cells transiently transfected with the ER alpha promoter plasmid bearing 2 half ERE-mutated sites (C 2mut half-ERE) or with a deleted construct of ER alpha promoter containing Sp-1 site (p-245/? 212, A) that ER beta-mediated down-regulation still persisted. In contrast, deletion of the Sp-1 site (C Sp-1 del) completely abrogated ER beta's effects (Fig. 2b) . Similar results were obtained in the ZR75 breast cancer cells (data not shown). Taken together, our findings demonstrated that the down-regulatory effects of ER beta on ER alpha gene expression requires an Sp1 sequence motif. Since functional domains of Sp1 are involved in proteinprotein interactions with other transcription regulatory molecules, such as the corepressors SMRT, NCoR and BCoR (BCL6 corepressor) [41] [42] [43] [44] , to inhibit cell transcription machinery, we next addressed whether the same corepressors may be recruited by the ER beta/Sp1 complex to ER alpha gene promoter. Fig. 1 Overexpressed ER beta down-regulates ER alpha expression in breast cancer cells. a Bottom panel, total RNA was isolated from MCF-7 and ZR75 cells transfected with either empty vector (-) or ER beta expression plasmid and reverse transcribed. cDNA was subjected to PCR using specific primers for ER alpha, ER beta and GAPDH. NC, negative control, RNA sample without the addition of transcriptase. Upper panel, the histograms represent the mean ± S.D. of three independent experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as the percentage of the control assumed to be 100 %. b Bottom panel, western Blot analysis of ER alpha and ER beta in total protein extracts from MCF-7 and ZR75 cells, transiently transfected with either empty vector (-) or ER beta expression plasmid. GAPDH was used as loading control. Upper panel, the histograms represent the mean ± S.D. of three independent experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as the percentage of the control assumed to be 100 %. c Left panel, Total RNA was isolated from MCF-7 and ZR75 cells transfected with either empty vector (-) or ER beta expression plasmid and reverse transcribed. cDNA was subjected to PCR using specific primers for IRS-1, pS2, Cyclin D1, and GAPDH. NC, negative control, RNA sample without the addition of transcriptase. The NCoR corepressor is recruited with Sp-1 to ER alpha promoter region
The specific role of the Sp-1 motif in mediating the inhibitory role of ER beta on ER alpha gene expression was investigated using electromobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) assays. Using synthetic radiolabeled oligonucleotides bearing the Sp-1 motif present in the ER alpha promoter region (Fig. 3a, lane 1) , we observed the formation of a protein complex in nuclear (-) or ER beta expression plasmid were cross-linked with formaldehyde, and lysed. The pre-cleared chromatin was immune-precipitated with specific anti-Sp-1, antiNCoR, anti-SMRT, anti-Polymerase II, and anti-AcH4 antibodies, and with a normal mouse serum (IgG) as a negative control. A 5 ll volume of each sample and input were analyzed by PCR with specific primers, as detailed in Sect. ''Materials and methods,'' to amplify ER alpha promoter sequence containing Sp-1 site. Right panel, the histograms represent the mean ± S.D. of three separate experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as percentage of the control, which was assumed to be 100 %. c Left panel, Chromatin immunoprecipitated with anti-Sp-1 antibody was re-immunoprecipitated with anti-NCoR or anti-ER beta antibodies. A normal mouse serum (IgG) was used as a negative control. A 5 ll volume of each sample and input were analyzed by PCR with specific primers, as detailed in Sect. ''Materials and methods,'' to amplify ER alpha promoter sequence containing Sp-1 site. Right panel, the histograms represent the mean ± S.D. of three separate experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as percentage of the control, which was assumed to be 100 %. *P \ 0.01 ER betatransfected cells compared to empty vector (-)-transfected cells extracts from MCF-7 cells, which was abrogated by incubation with 100 fold molar excess of unlabeled probe (Fig. 3a, lane 2) , demonstrating the specificity of the DNAbinding complex. This inhibition was no longer observed when mutated oligodeoxyribonucleotide probe was used as competitor (Fig. 3a, lane 3) . Interestingly, overexpression of ER beta strongly increased the DNA-binding protein complex compared with control samples (Fig. 3a, lane 4) . The inclusion of anti-Sp-1, ER beta, NCoR and SMRT antibodies in the reaction immunodepleted the specific band, confirming the presence of these proteins in the complex (Fig. 3a, lanes 5-8) . Of note, immunodepletion occurred to a higher extent in the presence of NCoR than of SMRT antibodies. Non-specific IgG did not affect Sp-1 complex formation (Fig. 3a, lane 9) . Recombinant Sp-1 protein revealed a complex migrating at the same level as that of nuclear extracts from cells (Fig. 3a, line 10) .
Moreover, to better evaluate the involvement of Sp-1 and NCoR/SMRT corepressors in ER beta-mediated ER alpha down-regulation at the promoter level, ChIP assays were performed. Using specific antibodies against Sp-1, NCoR, SMRT, RNA-polymerase II, and acetyl histone H4, protein-chromatin complexes were immunoprecipitated from MCF-7 cells transfected either with an empty vector or an ER beta expression vector (Fig. 3b) . PCR using primers spanning the Sp-1 binding element in the ER alpha promoter region clearly showed an enhanced recruitment of Sp-1 and NCoR and slightly of SMRT upon ER beta overexpression. The corepressor DAX-1 was not detected under the same experimental conditions (data not shown). These results were concomitant with a lower association of RNA-Polymerase II and acetyl histone H4 to the ER alpha regulatory region, indicating that the chromatin in this region is probably in a less permissive environment for gene transcription. Re-ChIP assays confirmed the increased NCoR and ER beta occupancy of the Sp-1-containing region within the ER alpha promoter in cells overexpressing ER beta (Fig. 3c) .
NCoR knockdown reverses ER beta's effects on ER alpha down-regulation and cell proliferation
To ascertain the involvement of NCoR on ER beta-related downregulation of ER alpha, NCoR siRNA knockdown experiments were performed in MCF-7 cells transfected with an ER beta expression vector. Silencing of NCoR gene expression (evaluated by western blot and RT-PCR analysis, Fig. 4a, b) restored both protein and mRNA expression of ER alpha, while no changes were observed after transfection of cells with a scrambled siRNA control (Fig. 4c, d) . We also showed that the increased Sp-1 recruitment to ER alpha gene promoter was abrogated in presence of NCoR siRNA in MCF-7 cells overexpressing ER beta (Fig. 4e) . Concomitantly, the recruitment of RNApolymerase II in the same region was restored (Fig. 4f) .
Finally, the anti-proliferative effects exerted by ER beta were completely reversed in the presence of NCoR siRNA knockdown in MCF-7 and ZR75 breast cancer cells (Fig. 4g, h ), suggesting a crucial role for NCoR in mediating the ER beta-induced inhibitory effects on breast cancer cell proliferation.
ER beta antagonizes IGF-1 mediated up-regulatory effects on ER alpha expression and three-dimensional cell growth It has been previously demonstrated that IGF-1 and insulin can increase ER alpha expression and stimulate proliferation in breast cancer cells [45] [46] [47] [48] . Thus, we investigated the ability of ER beta to reverse IGF-1 effects on ER alpha expression in MCF-7 cells, by western blotting and real time PCR analysis (Fig. 5a, b) . As expected, IGF-1 Fig. 4 Effects of NCoR silencing on ER beta-mediated downregulation of ER alpha expression, Sp-1 recruitment to ER alpha promoter and cell proliferation. a Western blot analysis for NCoR in MCF-7 cells transfected with non-specific siRNA (C) or targeted against human NCoR (100 nM) for 16 and 32 h. GAPDH was used as a loading control. b RT-PCR for NCoR or GAPDH in MCF-7 cells transfected as above described. NC: negative control, RNA sample without the addition of reverse transcriptase. The histograms represent the mean ± S.D. of three independent experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as the percentage of the control assumed to be 100 %. *P \ 0.01 NCoR siRNA-transfected cells compared to nonspecific siRNA (C)-transfected cells. c Western blot analysis for ER alpha in MCF-7 cells transfected with either empty vector(-) or ER beta expression plasmid in presence of non-specific or NCoR siRNA. GAPDH was used as loading control. The histograms represent the mean ± S.D. of three independent experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as the percentage of the control assumed to be 100 %. d RNA was extracted from MCF-7 cells transfected with either empty vector(-) or ER beta expression plasmid in presence of non-specific or NCoR siRNA, reverse transcribed and cDNA was subjected to qRT-PCR for analyzing ER alpha mRNA levels. Data represent the mean ± S.D. of values from three separate RNA samples expressed as percentage of control (-) assumed to be 100 %. Each sample was normalized to GAPDH mRNA content. e, f MCF-7 cells transfected with either empty vector(-) or ER beta expression plasmid in presence of non-specific or NCoR siRNA, were crosslinked with formaldehyde, and lysed. The precleared chromatin was immunoprecipitated with anti-Sp-1 (e) or anti-RNA-polymerase II (Pol II, f) antibodies. A 5 ll volume of each sample and input was analyzed by qRT-PCR using specific primers to amplify ER alpha promoter sequence, including the Sp-1 site. Similar results were obtained in two independent experiments. g, h MTT assays in MCF-7 and ZR75 cells transfected as indicated. Results are expressed as fold change ± S.D relative to empty vector-transfected cells and are representative of three different experiments each performed in triplicate. *P \ 0.01 ER beta-transfected cells compared to empty vector-transfected cells. **P \ 0.01 NCoR siRNA-transfected cells compared to ER beta-transfected cells enhanced ER alpha protein and mRNA levels and ER beta overexpression significantly abrogated this increase. Then, the effects of ER beta on IGF-1-induced growth were assessed using three-dimensional MCF-7 cell culture, that simulate ''in vivo'' the biological features of tumors. Our results showed that ER beta overexpression blocked the IGF-1 induced cell growth, as evidenced by the extent of aggregation scored by measuring the spheroid diameters (Fig. 5c ).
Discussion
In this study, we show for the first time that ER beta overexpression down-regulates ER alpha gene expression in a ligand-independent manner in ER alpha-positive breast cancer cells. This occurs through ER beta interactions with Sp-1 and an enhanced NCoR corepressor recruitment within the human ER alpha promoter region, up-stream of the initiating transcription site. ER alpha and ER beta have both overlapping and distinct expression patterns, and mammary gland development in animal models requires ER alpha signaling. It has been hypothesized that dysregulated ER isoform expression may induce abnormal cell proliferation and survival, thus impacting mammary tumorogenesis. It is also well known that ER alpha expression is increased and ER beta expression is decreased in early breast cancers, whereas expression of both receptors declines in more invasive cancers [49] [50] [51] . Expression of ER beta is lost in other early tumor types in respect to normal tissue [52] [53] [54] , leading to the hypothesis that ER beta may function as a tumor suppressor [26, 27] . Data coming from cell studies have suggested that ER beta negatively interferes with ER alpha signaling in breast cancer cells, and mediates antiproliferative effects [27, 33] . ER beta over-expression inhibits tumor establishment and growth as well as E2-induced tumor formation ''in vivo'' in mouse xenografts of ER alpha-positive MCF-7 and T47D breast cancer cells [25, 29, 55] . Indeed, ER beta induces inhibition of classical estrogen-regulated genes, such as VEGF and PDGFb [31] . Recently, Song and Pan [56] demonstrated that ER alphamediated estrogenic activity in the mammary gland can be opposed by ER beta, and it has been suggest that selective agonists such as DPN should be explored for the development of better hormone replacement therapy regimens to reduce or eradicate the risk for breast cancer. In the majority of clinical studies, ER beta expression indicates a favorable response to adjuvant tamoxifen (Tam) therapy, and patients with ER alpha ?/ER beta ? tumors appear to respond at least as well as or better to endocrine therapy than patients with ER alpha ?/ER beta-tumors. In addition, in Tam-treated patients, high ER beta expression correlates with increased overall, and disease-free survival, no disease progression, or no relapse within 5 years [24, [57] [58] [59] . Thus, ER beta has emerged as potential marker for predicting response to endocrine therapy.
These findings led us to investigate the molecular mechanism through which ER subtypes are regulated in breast cancer cells. Here, we have demonstrated that ER beta overexpression in a ligand-independent manner resulted in inhibition of ER alpha in terms of mRNA and protein content in breast cancer cells. Similar inhibitory effects were also obtained for the expression of estrogendependent genes such as IRS-1, pS2, and cyclin D1. These data underline how ER beta-induced ER alpha down-regulation might arise via transcriptional mechanisms. Therefore, we focused on the molecular mechanisms by which ER beta mediates repression of ER alpha gene expression and on the biological consequences of ER beta overexpression on growth of breast cancer cells.
ER alpha and ER beta are transcriptional factors that can regulate gene expression through several different modes including direct DNA-binding (acting as homodimers or as heterodimers) or through tethering to other transcription factors such as activating protein-1 (AP-1) and stimulating protein-1(Sp-1) [8, 60] . This has been most extensively investigated in relationship to protein complexes involving Sp-1 and ER alpha at GC boxes, which are classic binding sites for members of the Sp-1 family of transcription factors [61] [62] [63] . Many studies have observed that ER alpha is able to enhance binding of Sp1 to its site in several promoter regions [13] [14] [15] . The analysis of different functional motifs present within the ER alpha proximal promoter [37] has identified two half-ERE and one Sp-1 responsive elements, as potential targets of ER beta. Functional experiments using ER alpha promoter-deleted or mutated constructs have shown that Sp-1 sequence is an important prerequisite for the down-regulatory effects of ER beta on ER alpha promoter activity. These results were well supported by electrophoretic mobility shift assays, which revealed a marked increase in a specific DNA-binding complex in nuclear extracts from MCF-7 cells overexpressing ER beta. This complex was immune-depleted by anti-Sp-1 and anti-ER beta antibodies, suggesting the presence of these proteins in the complex. Furthermore, we observed an enhanced recruitment of Sp-1 and ER beta to the ER alpha promoter, that was concomitant with a decrease in RNA-polymerase II and acetyl histone H4 recruitment, further supporting a negative role for ER beta in modulating ER alpha gene transcriptional machinery.
A recent study reported that the ZFDBD (Zinc Finger DNA-Binding Domain) and ID (Inhibitory Domain) domains of Sp-1 are involved in protein-protein interactions with other transcription regulatory molecules, such as the corepressors SMRT, NCoR, and BCoR (BCL6 corepressor) [41] [42] [43] . These corepressors interact with unliganded nuclear receptors, through an elongated helix of sequence LXXI/HIXXXI/L, alternatively referred to as the CoRNR-box [64] [65] [66] . It has been recently documented that NCoR and SMRT are also recruited by both ER and PR in the presence of ligands to regulate transcription of different genes [67, 68] . Our results demonstrate that NCoR was the corepressor crucially recruited on the Sp-1 site of the ER alpha gene promoter together with Sp-1 and ER beta. In general, NCoR and SMRT share the same molecular architecture, interact with many of the same transcription factors, and assemble into similar corepressor complexes [69] . We also detected a slight recruitment of SMRT under the same experimental conditions. Finally, the contribution of the NCoR corepressor factor in ER beta-mediated effects emerges from experiments showing that silencing of NCoR gene expression was able to reverse the inhibitory effects of ER beta on ER alpha mRNA and protein content, Sp-1 recruitment to the ER alpha promoter gene and cell growth proliferation. Previous ''in vitro'' studies have shown that insulin and IGF-1 up-regulate the ER alpha expression as well as its DNA-binding capacity [45] [46] [47] [48] . We demonstrated how ER beta reduced the stimulatory effects induced by IGF1 on ER alpha expression and three-dimensional cell growth, and became a negative modulator of the well known crosstalk between ER alpha and IGF1-R signaling pathways.
In conclusion, we suggest that inhibition of ER alpha by ER beta is a critical regulatory pathway occurring in ERpositive cells, addressing prospectively that therapeutic tools which potentiate ER beta action and thereby deplete intratumoral ER alpha content may be useful to inhibit breast cancer cell growth and progression.
